1,088 Thermo Fisher Scientific Inc. $TMO Shares Sold by Stevens Capital Partners

Stevens Capital Partners cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 75.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 357 shares of the medical research company’s stock after selling 1,088 shares during the quarter. Stevens Capital Partners’ holdings in Thermo Fisher Scientific were worth $241,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TMO. Tsfg LLC grew its stake in shares of Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock worth $56,000 after purchasing an additional 19 shares in the last quarter. Renasant Bank increased its stake in Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock valued at $970,000 after buying an additional 20 shares during the period. Strengthening Families & Communities LLC raised its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after buying an additional 21 shares in the last quarter. TCI Wealth Advisors Inc. lifted its stake in shares of Thermo Fisher Scientific by 5.4% in the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after acquiring an additional 22 shares during the period. Finally, Legacy Wealth Managment LLC ID boosted its holdings in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on TMO. Citigroup upped their target price on Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. UBS Group reissued a “buy” rating and issued a $800.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, October 22nd. Guggenheim began coverage on Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating for the company. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Finally, HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $689.10.

Insider Activity

In related news, CEO Marc N. Casper sold 275 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 76,199 shares of company stock valued at $45,896,780 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.0%

Shares of Thermo Fisher Scientific stock opened at $696.78 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $711.85. The firm has a market capitalization of $257.63 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $654.87 and its 200-day moving average is $552.94.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same period in the prior year, the firm earned $5.79 earnings per share. The business’s quarterly revenue was up 9.1% on a year-over-year basis. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.